目的 分析研究跨膜紧密连接蛋白-1（Claudin-1）和人骨髓内皮细胞标记物-1（HBME-1）在甲状腺乳头状癌（papillary thyroid carcinoma, PTC）组织中的表达和临床意义。方法 选取我院于2019.1.3- 2021.11.30期间行外科手术治疗的99例PTC患者作为研究对象，观察Claudin-1和HBME-1蛋白的表达情况。通过单因素以及相关性分析Claudin-1和HBME-1表达量与甲状腺乳头状癌临床病理特征之间的关系。结果 癌组织中Claudin-1和HBME-1的蛋白表达水平均高于癌旁组织（P＜0.001）。癌组织中Claudin-1和HBME-1的蛋白表达水平均与病灶大小和被膜侵犯有相关性，相关性分析表明在PTC中二者呈正相关。结论 Claudin-1和HBME-1在PTC癌组织中高表达，均与病灶大小及被膜侵犯密切相关，其异常表达可能共同参与PTC的发生以及恶性进展过程。
Objective: To investigate the expression and clinical significance of transmembrane tight junction protein-1 (Claudin-1) and human bone marrow endothelial cell marker-1 (HBME-1/MC) in papillary thyroid carcinoma (PTC). Methods A total of 99 patients with thyroid papillary carcinoma who underwent surgical treatment from January 2019 to November 2021 in our Hospital were selected as the study subjects. The focal tissues and normal tissues adjacent to the carcinoma were removed surgically. The expression of Claudin-1 and HBME-1 was observed by immunohistochemical staining. The relationship between claudin-1 and HBME-1 expression levels and general features of thyroid papillary carcinoma was analyzed by univariate analysis and correlation analysis. Results The protein expression levels of Claudin-1 and HBME-1 in cancer tissues were higher than those in adjacent tissues(P<0.001). Protein expression levels of Claudin-1 and HBME-1 in cancer tissues were correlated with lesion size and capsule invasion, and correlation analysis showed positive correlation between claudin-1 and HBME-1 in PTC. Conclusion Both Claudin-1 and HBME-1 are highly expressed in papillary thyroid carcinoma tissues, and are closely related to the size of tumor lesion and capsular invasion, its abnormal expression may jointly participate in the occurrence of PTC and the process of malignant progression.
Key words： Papillary thyroid carcinoma; clinical significance; Claudin-1; HBME-1
 Maia FF, Zantut-Wittmann DE.Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy[J]. Clinics, 2012, 67(8):945-954.
 Zhu X, Yao J, Tian W. Microarray technology to investigate genes associated with papillary thyroid carcinoma[J]. Mol Med Rep, 2015, 11(5):3729-3733.
 Raposo L, Morais S, Oliveira M J, et al. Trends in thyroid cancer incidence and mortality in Portugal[J]. Eur J Cancer Prev, 2016, 26(2):135-143.
 Bhat AA, Syed N, Therachiyil L,et al. Claudin-1, a double-edged sword in cancer[J]. Int J Mol Sci, 2020, 21,569.
 Du YL, Liang Y, Cao Y,et al. LncRNA XIST Promotes migration and invasion of papillary thyroid cancer cell by modulating miR-101-3p/CLDN1 axis[J]. Biochem Genet, 2021, 59(2):437-452.
 Hasimoto Y,Okada Y, Shirakura K, et al. Anti-claudin antibodies as a concept for development of claudin- directed drugs[J]. Pharmacol Exp Ther, 2019, 368(2): 179-186.
 郭欣，吴志宇等.Claudin-1蛋白在甲状腺癌中的表达及调控.临床研究论著[J]. 2014, 30(5): 414-416.